Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study.

Vandenplas, Yannick; Simoens, Steven; Van Wilder, Philippe; Vulto, Arnold G; Turk, Florian; Huys, Isabelle

Vandenplas, Yannick; Simoens, Steven; Van Wilder, Philippe; Vulto, Arnold G; Turk, Florian; Huys, Isabelle.

Afiliação

Vandenplas Y; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, Germany. yannick.vandenplas@kuleuven.be.
Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, Germany.
Van Wilder P; Ecole de Santé Publique, Université Libre de Bruxelles (ULB), Brussels, Belgium, Germany.
Vulto AG; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, Germany.
Turk F; Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
Huys I; Unversity of Paderborn, Paderborn, Germany.

BMC Health Serv Res ; 22(1): 1211, 2022 Sep 29.

Article em En | MEDLINE | ID: mdl-36175885

Assuntos

Medicamentos Biossimilares; Médicos; Bélgica; Humanos; Medicamentos sem Prescrição; Padrões de Prática Médica

Palavras-chave

Behavior; Belgium; Biological medicine; Biosimilar; Policy; Prescription

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Médicos / Medicamentos Biossimilares Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research / Systematic_reviews Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google